التفاصيل البيبلوغرافية
| العنوان: |
Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer. |
| المؤلفون: |
Kanakaveti, Vishnupriya, Ramasamy, Sakthivel, Kanumuri, Rahul, Balasubramanian, Vaishnavi, Saravanan, Roshni, Ezhil, Inemai, Pitani, Ravishankar, Venkatraman, Ganesh, Rayala, Suresh Kumar, Gromiha, M. Michael |
| المصدر: |
Cancers; Nov2022, Vol. 14 Issue 21, p5241, 21p |
| مصطلحات موضوعية: |
THERAPEUTIC use of antineoplastic agents, PROTEINS, BIOLOGICAL models, IN vivo studies, XENOGRAFTS, ANIMAL experimentation, ANTINEOPLASTIC agents, APOPTOSIS, COENZYMES, BREAST tumors, MICE, PHARMACODYNAMICS, CHEMICAL inhibitors |
| مستخلص: |
Simple Summary: Our work has led to the identification of three novel BH4 mimetics, SM216, SM396, and SM949, with nanomolar activities both in vitro and in vivo assays. SM396 binds covalently to the BH4 domain of BCL-2 while the compounds SM216 and SM949 are non-covalent BH4 binders. Our results illustrate that these compounds are highly specific to the triple-negative breast cancer cells with no effect on normal cells. Elevated levels of Cyt-c induced by these compounds suggest significant inhibition of BCL-2 leading to apoptosis. Further investigations of these potent lead compounds will lead to clinical translations in targeting challenging tumor types. Targeting the challenging tumors lacking explicit markers and predictors for chemosensitivity is one of the major impediments of the current cancer armamentarium. Triple-negative breast cancer (TNBC) is an aggressive and challenging molecular subtype of breast cancer, which needs astute strategies to achieve clinical success. The pro-survival B-cell lymphoma 2 (BCL-2) overexpression reported in TNBC plays a central role in deterring apoptosis and is a promising target. Here, we propose three novel BH4 mimetic small molecules, SM396, a covalent binder, and two non-covalent binders, i.e., SM216 and SM949, which show high binding affinity (nM) and selectivity, designed by remodeling the existing BCL-2 chemical space. Our mechanistic studies validate the selectivity of the compounds towards cancerous cells and not on normal cells. A series of functional assays illustrated BCL-2-mediated apoptosis in the tumor cells as a potent anti-cancerous mechanism. Moreover, the compounds exhibited efficacious in vivo activity as single agents in the MDA-MB-231 xenograft model (at nanomolar dosage). Overall, these findings depict SM216, SM396, and SM949 as promising leads, pointing to the clinical translation of these compounds in targeting triple-negative breast cancer. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder